Background In real practice, two or more antihypertensive drugs are needed to achieve target blood pressure. We investigated the comparative beneficial actions of combination therapy of renin-angiotensin system inhibitors (RASI), with calcium channel blockers (CCB) over CCB monotherapy on the development of new-onset diabetes mellitus (NODM) in Korean patients during four-year follow-up periods.
well known important risk factors of cardiovascular diseases (CVD) and often these disease entities have intimate relationships with each other. [1] [2] [3] According to a previous study the development of type 2 DM (T2DM) was about 2.5 times higher in hypertensive patients compared to normotensive patients. [4] In patients with T2DM, the incidence of CVD is about two-and four-times higher than the general population. [5] Therefore, hypertensive patients have a relatively higher risk of new-onset DM (NODM) and this may trigger further cardiovascular diseases. [6] Antihypertensive drug impacts on the blood glucose level are diverse according to the class of those drugs. [7] [8] [9] Among the antihypertensive drugs, the incidence of NODM is unchanged or increased by thiazide diuretics and beta-blockers (BB) [10, 11] and unchanged or decreased by calcium channel blockers (CCB), angiotensin converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARB). [12, 13] Grimm, et al. [14] also reported that diuretics and BB can increase the incidence of NODM, but ARB as well as ACEI has a preventive effect and CCB has a neutral position in the development of NODM. Further, they also suggested these effects are much stronger when both substance classes are used in combination. In addition, Burke, et al. [15] reported antihypertensive drugs combination therapy including ACEI had lowered the risk of NODM more than antihypertensive drug combinations without an ACEI. But other meta-analysis demonstrated the risk of NODM was lower in patients treated ARB compared with ACEI. [16] There are rare studies [17] on the relationship between antihypertensive therapies and the incidence of NODM in hypertensive Asian patients especially, in Korean population. The purpose of this study was to investigate the comparative efficacy of combination therapy of renin-angiotensin system inhibitors (RASI) which include ACEI or ARB, with CCB over CCB monotherapy on the development of NODM during four-year follow-up period in non-diabetic hypertensive Korean patients.
Methods

Study population
This study was a non-randomized, single center, observational and retrospective study. Finally, a total of 3208 consecutive hypertensive patients without a history of DM who had been prescribed CCB were retrospectively enrolled using the electronic database of Korea University Guro Hospital from January 2004 to December 2012. All enrolled patients had undergone a glucose tolerance test. Inclusion criteria were both hemoglobin (Hb) A1c ≤ 5.7% and a fasting glucose level ≤ 100 mg/dL and the exclusion criteria were the patients who had pre-diabetic disease, such as impaired glucose tolerance and impaired fasting glucose. The first prescription day within the study period was defined as the start day of the study. A total of 3208 hypertensive patients were divided into the two groups according to the additional use of RASI (RASI use group, n = 1221 and no use group, n = 1987) to CCB. The RASI use group was composed with ACEI prescribed patients (n = 255) or ARB prescribed patients (n = 966). To adjust for potential confounders, a propensity score-matched (PSM) analysis was performed using the logistic regression model (C-statics = 0.743). After PSM, 939 well-matched pairs (n = 1878) were generated and, the baseline characteristics of the two groups were balanced (Table 1) .
Study definitions and study endpoints
NODM was defined as fasting blood glucose (FBG) ≥ 126 mg/dL or HbA1c ≥ 6.5%. [18] The primary study endpoint was the cumulative incidence of NODM during a four-year clinical follow-up periods. The secondary endpoints was major adverse cardiac events (MACE) defined as total death, myocardial infarction (MI) and percutaneous coronary intervention (PCI). The mean follow-up duration was 1825 ± 1221 days in all groups before baseline adjustment and 1825 ± 1268 days in the PSM group. The mean prescription duration of the RASI group (CCB with RASI) was 1564 ± 1007 days and the no RASI group (CCB monotherapy) was 1689 ± 1040 days in all patients. After PSM, the mean prescription duration of the CCB with RASI group was 1568 ± 1016 days and the CCB group was 1796 ± 1043 days. We followed up on the clinical data of all enrolled patients through face-to-face interviews at outpatient clinics, medical chart reviews and telephone calls.
Statistical analysis
For continuous variables, differences between the two groups were evaluated with the unpaired t-test or the Mann-Whitney rank test. Data were expressed as mean ± SD. For discrete variables, differences were expressed as counts and percentages and analyzed with χ 2 or Fisher's exact test between the groups as appropriate. To adjust for potential confounders, PSM analysis was performed using the logistic regression model. All data were processed with the Statistical Package for the Social Sciences version 20.0 (IBM, Armonk, NY, USA). We tested all available variables that could be of potential relevance: gender, age, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, previous PCI, previous cerebrovascular accident (CVA), previous heart failure (HF), coronary artery spasm, atrial fibrillation and arrhythmia, current smokers, current alcoholics, laboratory findings [FBG, HbA1c, total cholesterol, triglyceride, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein-cholesterol, high-sensitivity C-reactive protein, Hb, serum creatinine] and medications (BB, diuretic, nitrate, lipid lowering agents, aspirin, clopidogrel, cilostazole). The logistic model by which the propensity score was estimated showed good a predictive value (C-statistic = 0.743). Patients with the CCB with RASI group were then one-to-one matched to the patients with the CCB group according to propensity 
Results
A total of 3028 eligible hypertensive patients who prescribed CCB were finally enrolled for the analysis. After PSM analysis, 939 matched pairs (n = 1878) were generated and their baseline characteristics, laboratory findings, and medication history are summarized in Table 1 . In the unmatched population, men, SBP, DBP, previous history of PCI, current alcoholics, FBG, HbA1c, triglyceride, Hb, serum creatinine and the prescription rates of BB, diuretics, lipid lowering agents, aspirin, and clopidogrel were significantly higher in CCB with RASI use group. The level of HDL-cholesterol and the use of nitrates were significantly higher in the CCB group. After PSM these differences were balanced. In the unmatched population, the use of ACEI was 20 2%) ]. The total prescription duration of each drug between the two groups was not significantly different before and after PSM (Table 1) . Table 2 and Figure 1 show the clinical outcomes by Kaplan-Meier curved analysis and Cox-proportional hazard analysis at four years. In the unmatched population, the incidences of NODM (8.6% vs. 6.8%, Log rank P = 0.149) were not statistically different between the two groups. However, the incidence of MACE (5.2% vs. 3.3%, Log rank P = 0.033), total death (1.2% vs. 0.3%, Log rank P = 0.003) and cardiac death (0.7% vs. 0.1%, Log rank P = 0.020) were significantly higher in the CCB with RASI group. After PSM, the incidences of NODM [8.5% vs. 8.3%, Log rank P = 0.962, hazard ratio (HR) = 1.009, 95% confidence interval 3.1%, P = 0.895) were also similar between the two groups. In Table 3 , the incidence of NODM was not significantly associated with specific types of drugs among RASI after PSM. Table 4 shows independent predictors of NODM before and after PSM. In the entire patients, the previous PCI history was a significant predictor for NODM before (HR = 0.639; 95% CI: 0.416-0.984; P = 0.042) and after adjustment (HR = 0.413; 95% CI: 1.175-0.976; P = 0.044). However, after PSM, there were no significant predictors for NODM in this study. Subgroup analysis for NODM in PSM patients shows similar results ( Figure 2 ). Figure 3 shows subgroup analysis for NODM in PSM patients. 
Discussion
The main findings of this study were: (1) the development of NODM was not significantly different between the two groups (CCB with RASI group vs. CCB group) and (2) the incidences of MACE, total death, MI, PCI were also similar between the two groups in non-diabetic hypertensive Korean patients during four-year follow-up period.
One of important features of this study was that many previous reports [10] [11] [12] [13] [14] which showed the positive causeeffect relationship between antihypertensive drugs and NODM could be extended to hypertensive Asian patients, especially Korean patients.
Several previous guidelines recommended CCB as one of the first-line drugs suitable for the beginning and maintenance of their antihypertensive role in hypertensive patients. [19, 20] In most patients, two or more antihypertensive drugs are needed to achieve target blood pressure and recent guidelines recommend combination therapy to control blood pressure levels. [19] [20] [21] Therefore, the baseline study population of this study was composed of patients whom had been prescribed CCB to control their blood pressure, in addition, this inclusion was based on the premise that CCB may be associated with reduced possibility of NODM compared with diuretics and BB. [10] Because there is some debate [15] [16] [17] 22] about the comparative superiority of beneficial effects between ACEI and ARB on the incidence of NODM in hypertensive patients, we considered these two drugs, ACEI and ARB, as a one group (RASI group) and then we compared the different incidences of NODM between the CCB with RASI and CCB group. DM in addition to hypertension may amplify the progression of vascular damage. Coexistence of DM and hypertension also are important factors of arterial stiffness and endothelial dysfunction compared with hypertensive nondiabetic patients. [23] Several possible cause-effect relationships between DM and hypertension were hypothesized including obesity and insulin resistance, inappropriate activation of the renin-angiotensin-aldosterone system, oxidative stress, increased sympathetic nervous system activation, and abnormal renal handling of sodium. [24] Also hypertension causes endothelial dysfunction, remodeling of small arteries and/or sustained sympathetic nervous system acti-Journal of Geriatric Cardiology | jgc@jgc301.com; http://www.jgc301.com vation; these factors can cause insulin resistance and diabetes by reducing insulin delivery to muscles or causing pancreatic microvascular dysfunction. [4] Previous studies reported that CCB combined with ARB had metabolically neutral effects. [6] Our study also showed that the use of RASI in addition to CCB did not show a significant reduction of the development of NODM. Although several possible mechanisms that cause change in insulin sensitivity were suggested, the precise mechanisms are not clear currently. [7] Although we cannot precisely explain this result, we cautiously speculate several possible factors related to our results. Firstly, there may be similar or common pathways increasing insulin sensitivity between CCB and RASI and these pathways fail to show synergistic effects on insulin sensitivity of both drugs and may also leads to insignificant differences on the incidence of NODM. Secondly, as we know, there is some debate [15] [16] [17] 22] about comparative superiority of beneficial effects between ACEI and ARB on the incidence of NODM in hypertensive patients, the countervailing effect may have nullified the beneficial effect between these two groups. Thirdly, there are so many different kinds and numbers of drugs that compose the RASI group and diverse drug interactions also can decrease their beneficial effects on insulin sensitivity by interacting with each other (Table 3) . Last but not least, this study was a single center retrospective study, so this may be another factor of this result.
Owing to the incidence of NODM differed in the studies and because they were sometimes combined with other antihypertensive drugs and no monotherapy was considered, the accurate estimation of the annual incidence to the different substance classes may be difficult. In general, independent from the substance class, the incidence was estimated at 1.7% annually. [14] The incidence of NODM during treatment with CCB varies from 0.9% to 2.0% per year and from 1.1% to 1.7% per year by ACEI. [14] Ahmad, et al. [25] reported that the incidence of NODM was increased with the duration of antihypertensive drug therapy (three-and five-years) and the incidence of NODM was 12.5% by CCB during one-and five-years follow-up period. In our study, the incidence of NODM was similar with his study (8.6% vs. 6.8%, Table 2 ) during the four-year follow-up periods. In our study, the higher rate of total death in RASI group before PSM may be caused by relatively higher baseline risk factors such as, SBP, DBP, previous PCI, current alcoholics, triglyceride, and the use of diuretics, statin, aspirin, and clopidogrel which were contained in this group.
Despite the above cited limitations, our study included real-world combination drug therapy in hypertensive Korean patients. We believe this study to be the first comparative study to investigate whether or not there are additional beneficial effects of RASI on the incidence of NODM over CCB monotherapy during four-year follow-up period in Korea.
Limitations
Our study has several limitations. Firstly, we have some deficits in several parameters such as family history, abdominal circumference, and socioeconomic status. Secondly, the study population of this study was relatively low-risk patients, so these results could be different in high-risk patients. Thirdly, though the first antihypertensive prescription for nearly all patients was monotherapy, the decision to add a second antihypertensive drug was dependent up on each physician's discretion; this could affect the end results and add a bias to this study. Fourthly, the RASI group was composed of so many diverse kinds and numbers of drugs and this factor also add bias. Last but not least, because this study was a single center retrospective study, large, randomized, and controlled clinical trials will be required for a more definitive conclusion.
Conclusions
In conclusion, the use of RASI in addition to CCB showed comparable incidence of NODM and MACE compared to CCB monotherapy in non-diabetic hypertensive Korean patients up to four years. However, large-scaled randomized controlled clinical trials will be required for a more definitive conclusion.
